Submit Deal

SIXPEAKS BIO AG

HQ - Basel

Summary

SixPeaks Bio is a company developing mAb-peptide-based polyfunctional products for cardiometabolic diseases including obesity diabetes and cardiovascular disease.

Deals Overview

Total Deals2

Valued Deals2

Total Value£ 314 M

Avg. Deal Size£ 157 M

Market Context

Senior Management

Philip Larsen
CEO

Sort

22 May 2024|Switzerland|Health Care Services

Target: SIXPEAKS BIO AG

Bidder: VERSANT VENTURES

5 Service Providers

2 Target | 3 Bidder

12 Dealmakers

2 Target | 10 Bidder

£ 86 M

Value

10 Nov 2025|Switzerland|Health Care Services

Target: SIXPEAKS BIO AG

Bidder: ASTRAZENECA PLC

3 Service Providers

1 Target | 2 Bidder

10 Dealmakers

1 Target | 9 Bidder

£ 227 M

Value